Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Sherene Loi(The University of Melbourne), Christos Sotiriou(Université Libre de Bruxelles), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), Christine Desmedt(Université Libre de Bruxelles), K W Ryder(Guy's Hospital), Pratyaksha Wirapati(SIB Swiss Institute of Bioinformatics), Cheryl Gillet(Guy's Hospital), Gianluca Bontempi(Université Libre de Bruxelles), Mauro Delorenzi(SIB Swiss Institute of Bioinformatics), Maurice P.H.M. Jansen(Erasmus MC Cancer Institute), Martine Piccart(Institut Jules Bordet), James F. Reid(IFOM), John A. Foekens(National Cancer Centre Japan), Andrew M Tutt(Guy's Hospital), Els M.J.J. Berns(Erasmus MC), Marco A. Pierotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Françoise Lallemand(Institut Jules Bordet), Benjamin Haibe‐Kains(Ontario Institute for Cancer Research)
Cited by 406
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k